CytomX Therapeutics

Company snapshot

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 62 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CytomX Therapeutics. Not investment advice.

• Peer + 0 momentum

  Topiloric/Uriadec

  TA overlap score 22.4

• Peer + 0 momentum

  Corbus Pharmaceuticals

  TA overlap score 22.2

• Peer + 0 momentum

  Pyxis Oncology

  TA overlap score 21.6

• Peer + 0 momentum

  PURPLE BIOTECH

  TA overlap score 20.6

Recent activity

Latest pipeline, patent, and corporate events for CytomX Therapeutics.

1. May 23, 2026 Clinical update

   CX-072 — Phase 2

2. May 23, 2026 Clinical update

   CX-2009 — Phase 2

3. May 23, 2026 Clinical update

   CX-2009 — Phase 2

4. May 23, 2026 Clinical update

   CX-2029 — Phase 2

5. May 23, 2026 Clinical update

   CX-188 — Phase 1

View all clinical trial activity →

• What is CytomX Therapeutics?

  CytomX Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker CTMX. Primary therapeutic focus areas include Solid Tumor, Adult, Solid Tumor, Neoplasms, Solid Tumors. NovaPharmaNews links 8 clinical program(s), 0 drug profil

• Is CytomX Therapeutics publicly traded?

  Yes. CytomX Therapeutics is listed with ticker CTMX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does CytomX Therapeutics develop or market?

  No drug profiles are currently linked to CytomX Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for CytomX Therapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does CytomX Therapeutics focus on?

  CytomX Therapeutics focuses on Solid Tumor, Adult, Solid Tumor, Neoplasms based on our analysis of their pipeline programs and drug development activities.